Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view.
What's in the News
- Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).
- The company announced expanded launch and first shipment of its next-generation Leo System, which now includes dual-channel fluorescence detection alongside chemiluminescence to increase multiplexing options, data throughput and flexibility for protein analysis in up to 100 capillaries within three hours (Key Developments).
- Bio-Techne and Nucleai are presenting data from the SECOMBIT clinical trial at the SITC 2025 Annual Meeting, using the COMET platform and AI-driven multimodal biomarker analysis to link spatial immune cell interactions in metastatic melanoma with clinical outcomes across different treatment arms (Key Developments).
- Bio-Techne launched the ProximityScope assay for use on Leica Biosystems' BOND RX platform, providing subcellular resolution of protein protein interactions and integration with ACD's RNAscope Multiomic LS kit for combined RNA and protein detection on the same tissue section (Key Developments).
- Saguaro Biosciences entered a distribution agreement with Bio-Techne to use Bio-Techne's global sales and marketing channels to distribute Saguaro's non toxic, wash free dyes for cell based assays, including ChromaLIVE, NucleoLIVE and MortaLIVE (Key Developments).
Valuation Changes
- Fair Value Estimate kept unchanged at about US$69.17 per share, indicating no adjustment to the central valuation anchor in this update.
- Discount Rate adjusted slightly from 7.83% to about 7.84%, reflecting a very small change in the assumed risk profile used in the model.
- Revenue Growth updated from about 6.40% to about 6.02%, signaling a modest recalibration of expected top line expansion in the long-term model inputs.
- Net Profit Margin revised from about 18.74% to about 18.94%, implying a slightly higher long-run profitability assumption in the forecasts.
- Future P/E kept effectively stable at around 47.1x, with only a minimal numerical adjustment that does not materially alter the valuation framework.
Have other thoughts on Bio-Techne?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeComments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.